N-Acetyl Selank --- Research Product Overview
**Disclaimer:** This article is provided for educational and research purposes only. [N-Acetyl Selank](/catalog/na-selank) is not approved by the FDA for human use. Nothing in this article constitutes medical advice or a recommendation for self-administration. All references are to published preclinical and clinical research conducted under appropriate regulatory frameworks. Viking Labs sells research-grade material exclusively for in-vitro and laboratory animal research use.
Introduction
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1990s. Its design appended the C-terminal tripeptide Pro-Gly-Pro (a fragment of tuftsin) to the human tuftsin sequence Thr-Lys-Pro-Arg, with the explicit goal of stabilizing the parent peptide against rapid plasma proteolysis while preserving its immunomodulatory and anxiolytic properties. Selank itself is registered in the Russian Federation as an anxiolytic medication and has been the subject of multiple Russian-language clinical investigations in generalized anxiety disorder and neurasthenia.
N-Acetyl Selank refers to a chemical modification in which the N-terminal threonine alpha-amine is acetylated. Acetylation removes a primary amine that is otherwise a substrate for aminopeptidases, further extending plasma and tissue half-life relative to the unmodified parent. The N-acetyl variant is the form most commonly encountered in research-grade peptide catalogs and is sometimes referred to in the literature as "N-Acetyl Selank Amidate" when the C-terminus is also amidated. For an extended comparison with the related Russian heptapeptide Semax, see Selank vs. Semax.
Sequence and Physicochemical Properties
The base Selank sequence is H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH, with a molecular weight of approximately 751.9 Da. The N-acetylated form (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH) carries an additional 42 Da from the acetyl moiety, yielding ~793.9 Da. C-terminally amidated variants differ by ~1 Da. The molecule carries a net positive charge at physiological pH driven by the lysine and arginine side chains, contributing to good aqueous solubility but also non-specific binding to negatively charged surfaces.
Research-grade material targets HPLC purity of >=98 percent and is supplied as a white-to-off-white lyophilized powder. Investigators should confirm sequence identity by mass spectrometry, purity by RP-HPLC, and residual solvent and counter-ion content via the Certificate of Analysis. The guide to peptide purity covers acceptable thresholds for in-vitro and animal research applications.
Mechanism of Action
Selank's pharmacology has been characterized across multiple molecular systems:
GABA-ergic modulation. Volkova et al. (2016) used real-time PCR to profile expression of 84 neurotransmission-related genes in rat frontal cortex following Selank administration. They reported altered expression of Drd1a, Drd2, Slc6a13, and Ptgs2 within one hour of dosing, suggesting that Selank engages dopaminergic and GABA-transporter signaling rather than acting purely through a single receptor.
[BDNF](/research/glossary#bdnf-brain-derived-neurotrophic-factor) up-regulation. Selank rapidly elevates brain-derived neurotrophic factor (BDNF) mRNA in rat hippocampus, which is mechanistically consistent with its observed nootropic effects. BDNF is the dominant neurotrophin governing synaptic plasticity and is broadly implicated in anxiolytic and antidepressant pharmacology.
Enkephalinase inhibition. Selank inhibits leucine-enkephalin degradation by plasma enkephalinase, thereby increasing endogenous enkephalin tone. This indirect opioid-system modulation has been proposed as a mechanism for the rapid anxiolytic onset reported in clinical studies.
Immunomodulation. Reflecting its tuftsin lineage, Selank modulates cytokine balance, with reported effects on IL-6 and interferon profiles in animal models of stress.
Preclinical and Clinical Research Summary
In rodent models, Selank produces dose-dependent anxiolytic effects in elevated plus maze, open field, and conflict paradigms, with potencies broadly comparable to benzodiazepines such as medazepam but without observable sedation, motor impairment, or withdrawal effects on discontinuation. Cognitive enhancement has been reported in passive-avoidance and Morris water-maze tasks.
Russian clinical investigations have evaluated Selank in generalized anxiety disorder and neurasthenia, with the most cited study (Zozulia et al., 2008) reporting anxiolytic efficacy comparable to medazepam alongside additional anti-asthenic and mild psychostimulant effects. These studies were not conducted under FDA or EMA frameworks and have not been replicated in Western regulatory contexts.
Common Research Applications
Selank and N-Acetyl Selank are commonly used in research to:
- Probe non-benzodiazepine anxiolytic mechanisms in rodent behavioral paradigms.
- Investigate BDNF-dependent plasticity and learning models.
- Study dopamine D1/D2 transcriptional regulation in cortical and hippocampal tissue.
- Explore intranasal delivery pharmacokinetics for centrally-active peptides.
Comparator Peptides and Molecules
Selank's research-tool value emerges most clearly in comparison with adjacent neuropeptide and small-molecule anxiolytics.
Selank vs. Semax. Semax is the closest pharmacological cousin --- another Russian-developed regulatory peptide derived from ACTH(4--10) with the C-terminal Pro-Gly-Pro stabilizing motif. Semax is more strongly nootropic and pro-cognitive, with a primary mechanism centered on BDNF and NGF up-regulation in cortical and hippocampal tissue, while Selank is more anxiolytic with secondary nootropic effects. The two peptides are often used together as a research stack and represent complementary tools for separating cognitive-enhancement from anxiolytic mechanisms. The full mechanistic comparison is covered in Selank vs. Semax.
Selank vs. benzodiazepines. The most-cited Russian clinical comparison is medazepam, a long-acting benzodiazepine. Selank produced comparable anxiolytic ratings on standard scales without the sedation, motor coordination impairment, and dependence-and-withdrawal profile that limit benzodiazepine utility in animal-model design. From a research-tools perspective, this means Selank can be used as a positive-control anxiolytic in behavioral paradigms where a benzodiazepine would confound motor or learning readouts.
Selank vs. [neuroplasticity](/research/neuroplasticity-peptides) peptides broadly. Within the broader class of small peptides that modulate plasticity through neurotrophin pathways, Selank sits near the BDNF-induction end of the spectrum. See neuroplasticity peptides and Dihexa cognitive research for the angiotensin-IV-derived comparator with hepatocyte-growth-factor-mediated synaptogenic activity.
Selank vs. [cerebrolysin](/research/cerebrolysin-neuroprotection). Cerebrolysin is a porcine-brain-derived peptide mixture used clinically in some European jurisdictions for cerebral ischemia and dementia. Where Selank is a defined synthetic heptapeptide, cerebrolysin is a complex undefined mixture --- the contrast between defined-sequence and biologically-derived peptide research tools is substantive for any rigorous mechanistic study. See cerebrolysin neuroprotection for the parallel research literature.
Selank vs. N-Acetyl Selank. Acetylation of the N-terminal threonine alpha-amine extends plasma half-life by removing the primary amine that aminopeptidases recognize. The acetyl variant is functionally equivalent to base Selank in receptor-and-pathway terms but offers practical advantages for animal-research dosing intervals.
Deeper Preclinical Breakdown
Three lines of preclinical evidence anchor the Selank literature.
Volkova et al. (2016), Frontiers in Pharmacology (PMC4757669). This is the most-cited modern transcriptomic study on Selank. The investigators administered 100 microg/kg Selank intraperitoneally to Wistar rats and harvested frontal cortex at 1, 3, and 6 hours post-dosing. Real-time PCR profiling of 84 neurotransmission-related genes revealed altered expression of dopaminergic genes (Drd1a, Drd2), GABA transporters (Slc6a13), prostaglandin synthesis (Ptgs2), and the orexin precursor Hcrt. The temporal pattern --- early (1-hour) effects on dopaminergic transcription and later (3-hour) effects on Hcrt --- supported a multi-pathway mechanistic model rather than single-receptor pharmacology. Limitations: gene-expression changes do not establish causal mechanism, and rat-cortex transcriptomics may not generalize across brain regions or species.
Kolomin et al. (2013). An earlier hippocampal transcriptome study established Selank's effect on plasticity-related gene expression and is the bridge between the original Russian clinical-pharmacology literature and the modern molecular work cited above. The Volkova group's later cortical study built directly on Kolomin's hippocampal results.
Kozlovskii and Danchev (2003). Behavioral characterization in rodent anxiety paradigms (elevated plus maze, open field, conflict-test) established dose-response relationships. Selank produced anxiolytic effects across 30--300 microg/kg without sedation or motor impairment, and pretreatment with the benzodiazepine antagonist flumazenil partially attenuated the anxiolytic response, supporting GABA-system involvement.
Formulation Considerations
Research-grade N-Acetyl Selank is supplied as a lyophilized white powder, typically in 5 mg or 10 mg sealed vials under inert atmosphere with desiccant. The acetylated N-terminus provides good chemical stability vs. the unprotected base form, but the basic side chains (lysine, arginine) can adsorb non-specifically to glass and certain plastic surfaces during reconstitution; this is mitigated by preparing stock solutions in low-binding polypropylene vials and adding 0.1 percent BSA carrier for very-dilute working solutions. Common synthetic impurities include des-acetyl Selank (visible as a separate RP-HPLC peak at slightly earlier retention) and truncation products. Residual TFA from cleavage chemistry and acetic acid from lyophilization buffers should be controlled by Karl Fischer water content and ion-chromatography assay on the Certificate of Analysis. See the peptide storage and reconstitution guide for detailed protocols.
Research-Context Dosing Ranges
Published preclinical and Russian clinical studies provide the following research-context dose anchors. Rodent intraperitoneal dosing has used 30--300 microg/kg for behavioral anxiolytic readouts, and 100 microg/kg/day across 7--14 days for chronic-administration transcriptomic studies. Intranasal rodent studies have used 250--750 microg/kg per dose, exploiting the route's first-pass-bypass advantage for centrally active peptides. In-vitro studies on cortical and hippocampal slice preparations have used 1--10 microM for electrophysiological and BDNF-induction readouts. Russian clinical investigations dosed Selank intranasally; those clinical doses are not relevant to research framing here and are described in the original Russian literature for historical context.
Cross-References
For broader context within the Viking Labs research library, see Selank vs. Semax for the closest pharmacological comparator, neuroplasticity peptides for the broader class, Dihexa cognitive research for an alternate plasticity mechanism, and cerebrolysin neuroprotection for the contrast between defined-sequence and biologically-derived peptide research tools. Handling and analytical protocols are covered in understanding peptide purity and the peptide storage and reconstitution guide.
Handling, Reconstitution, and Storage
Lyophilized N-Acetyl Selank is stable for >=24 months at -20 degrees C in sealed vials with desiccant. Reconstitution in bacteriostatic water (0.9 percent benzyl alcohol) at 1--5 mg/mL is standard for animal research; sterile water or PBS is appropriate for cell-culture work. Reconstituted material should be aliquoted to avoid repeated freeze--thaw cycles. The acetylated N-terminus confers good chemical stability in solution at neutral pH, but oxidation of the lysine side chain remains a concern over long storage.
Summary
N-Acetyl Selank is a stabilized, research-grade analog of the Russian heptapeptide Selank. Its preclinical pharmacology centers on GABA-system and BDNF-mediated anxiolytic and nootropic effects, with limited but suggestive clinical data from Russian sources. Its small size, water solubility, and well-defined synthesis make it a convenient research tool for probing peptide-based anxiolytic mechanisms.
*This article is provided for informational and research purposes only. Viking Labs does not sell products intended for human consumption.*